LifeStance Health Group (NASDAQ:LFST) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of LifeStance Health Group (NASDAQ:LFST – Free Report) from a buy rating to a strong-buy rating in a report issued on Saturday,Wall Street Zen reports.

Several other equities research analysts have also recently weighed in on the stock. Canaccord Genuity Group boosted their price target on shares of LifeStance Health Group from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Friday, November 6th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of LifeStance Health Group in a research note on Wednesday, November 4th. KeyCorp increased their price objective on shares of LifeStance Health Group from $15.00 to $17.00 and gave the company an “overweight” rating in a research report on Friday, November 6th. BTIG Research lifted their price objective on shares of LifeStance Health Group from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Thursday, November 5th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of LifeStance Health Group from $13.00 to $15.00 and gave the stock a “neutral” rating in a research note on Thursday, November 12th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $14.86.

Check Out Our Latest Report on LFST

LifeStance Health Group Stock Performance

NASDAQ LFST opened at $14.48 on Friday. The stock has a market capitalization of $5.51 billion, a PE ratio of 76.21 and a beta of 1.35. The business has a 50 day simple moving average of $12.83 and a two-hundred day simple moving average of $9.71. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.44 and a quick ratio of 1.44. LifeStance Health Group has a 1-year low of $6.01 and a 1-year high of $15.66.

LifeStance Health Group (NASDAQ:LFST – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.02. The business had revenue of $455.86 million for the quarter, compared to analysts’ expectations of $431.59 million. LifeStance Health Group had a return on equity of 4.82% and a net margin of 4.29%. The firm’s revenue for the quarter was up 25.3% compared to the same quarter last year. On average, research analysts predict that LifeStance Health Group will post 0.18 EPS for the current fiscal year.

Insider Activity

In other news, CTO Vukasin Paunovich sold 42,067 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $12.87, for a total transaction of $541,402.29. Following the transaction, the chief technology officer owned 205,379 shares of the company’s stock, valued at approximately $2,643,227.73. The trade was a 17.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Lisa Miller sold 14,663 shares of the stock in a transaction on Wednesday, November 11th. The shares were sold at an average price of $14.68, for a total value of $215,252.84. Following the sale, the chief operating officer owned 251,904 shares in the company, valued at $3,697,950.72. The trade was a 5.50% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 2,861,235 shares of company stock valued at $41,646,338. 3.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of LFST. IFP Advisors Inc lifted its holdings in shares of LifeStance Health Group by 316.5% in the 2nd quarter. IFP Advisors Inc now owns 3,694 shares of the company’s stock worth $40,000 after acquiring an additional 2,807 shares during the last quarter. KBC Group NV purchased a new position in shares of LifeStance Health Group during the 1st quarter worth about $29,000. Advisors Asset Management Inc. bought a new position in LifeStance Health Group during the 3rd quarter valued at about $64,000. Signaturefd LLC raised its position in LifeStance Health Group by 35.6% in the 3rd quarter. Signaturefd LLC now owns 5,357 shares of the company’s stock worth $64,000 after purchasing an additional 1,405 shares during the period. Finally, USA Financial Formulas purchased a new stake in LifeStance Health Group in the 3rd quarter worth about $71,000. Institutional investors own 85.50% of the company’s stock.

LifeStance Health Group Company Profile

(Get Free Report)

LifeStance Health Group, Inc. is a U.S. provider of outpatient mental health services. The company offers care through in-person clinics and virtual appointments, connecting patients with behavioral health professionals. Its services include psychotherapy, psychiatric evaluations and medication management. LifeStance’s clinicians treat a range of mental health conditions, including anxiety, depression, attention-deficit/hyperactivity disorder and mood disorders. Founded in 2017, LifeStance has expanded its network across the United States.

Further Reading

Analyst Recommendations for LifeStance Health Group (NASDAQ:LFST)

Receive News & Ratings for LifeStance Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeStance Health Group and related companies with MarketBeat.com's FREE daily email newsletter.